TCGA-EW-A1OV-01A-11R-A144-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 26
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.620
- INTERFERON_GAMMA_RESPONSE+0.540
- INTERFERON_ALPHA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.410
- COMPLEMENT+0.280
- G2M_CHECKPOINT+0.240
- KRAS_SIGNALING_UP+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- E2F_TARGETS+0.220
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.480
- PROTEIN_SECRETION-0.410
- CHOLESTEROL_HOMEOSTASIS-0.380
- ESTROGEN_RESPONSE_LATE-0.350
- UV_RESPONSE_DN-0.260
- TGF_BETA_SIGNALING-0.240
- HEDGEHOG_SIGNALING-0.230
- MYOGENESIS-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.230
- FATTY_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613787 | — | D | 0.875 |
| 2 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.874 |
| 3 | C3N-02922 | — | cohortMD2 | 0.870 |
| 4 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.868 |
| 5 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.868 |
| 6 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.855 |
| 7 | 20150122.TNBC | — | D | 0.854 |
| 8 | SRR8613734 | — | D | 0.853 |
| 9 | SRR1313153 | — | D | 0.846 |
| 10 | BSR_10_0136_B1_S95 | — | D | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |